BCRX
(NASDAQ)
1.96
-0.000100  (-0.01%)
Volume (24h): 2.09M Day Range: 1.91 - 2.03
Market Cap: 302.20M 52W Range: 1.38 - 9.25
Mar-26-20 11:33AM Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMTThomson Reuters StreetEvents
07:10AM Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMTThomson Reuters StreetEvents
Mar-25-20 04:47AM Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMTThomson Reuters StreetEvents
Mar-24-20 09:31PM Edited Transcript of BCRX earnings conference call or presentation 5-Mar-20 1:30pm GMTThomson Reuters StreetEvents
Mar-17-20 10:41AM Here's Why BioCryst Pharmaceuticals (NASDAQ:BCRX) Can Manage Its Debt Despite Losing MoneySimply Wall St.
Mar-16-20 11:10AM BEROTRALSTAT (BCX7353) SIGNIFICANTLY REDUCED USE OF ACUTE ON-DEMAND MEDICINE IN HAE PATIENTS IN APEX-2GlobeNewswire
Mar-13-20 06:30PM 7 Great Stocks for a Small BudgetZacks
11:12AM Cover Story: Triangle life sciences gasping for capital, leadersAmerican City Business Journals
Mar-10-20 04:00PM BioCryst (BCRX) Upgraded to Strong Buy: Here's WhyZacks
01:53PM Implied Volatility Surging for BioCryst (BCRX) Stock OptionsZacks
Mar-09-20 12:03PM The Dow, and Crude-Oil Prices, Are Plummeting. Some Biotechs Are in the Green.Barrons.com
11:41AM Top Ranked Momentum Stocks to Buy for March 9thZacks
Mar-05-20 01:25PM BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue EstimatesZacks
12:05PM BioCryst Reports Fourth Quarter and Full Year 2019 Financial Results and Upcoming Key MilestonesGlobeNewswire
Mar-05-20 12:00PM BioCryst Begins Proof of Concept Trial in PNH Patients With Oral Factor D Inhibitor, BCX9930GlobeNewswire
Mar-03-20 12:00PM BioCryst to Present at Barclays Global Healthcare ConferenceGlobeNewswire
Mar-02-20 09:15PM BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)GlobeNewswire
Feb-28-20 02:30PM BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% HigherZacks
Feb-27-20 05:30PM Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should KnowZacks
12:00PM BioCryst to Present New Data at American Academy of Allergy, Asthma & Immunology Annual MeetingGlobeNewswire
Feb-25-20 08:25PM 18 Medical Stocks To Watch Amid The Coronavirus OutbreakBenzinga
12:00PM BioCryst Appoints Alan G. Levin to Board of DirectorsGlobeNewswire
Feb-20-20 12:00PM BioCryst to Report Fourth Quarter and Full Year 2019 Financial Results on March 5GlobeNewswire
Feb-18-20 12:00PM FDA Accepts BioCryst’s NDA for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE AttacksGlobeNewswire
Feb-10-20 11:25AM How Many BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Shares Did Insiders Buy, In The Last Year?Simply Wall St.
Feb-06-20 12:00PM BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire
Feb-05-20 04:52PM Steven Cohen Renews His Interest in VerastemGuruFocus.com
Feb-03-20 12:00PM BioCryst Submits Japanese New Drug Application for Oral, Once Daily BerotralstatGlobeNewswire
Jan-23-20 03:00PM 13 Coronavirus-Related Stocks To Watch Amid Wuhan OutbreakBenzinga
Jan-15-20 12:00PM BioCryst Strengthens Commercial Rare Disease LeadershipGlobeNewswire
Jan-10-20 01:54PM Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?Zacks
Jan-06-20 12:00PM BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)GlobeNewswire
Jan-03-20 12:00PM BioCryst to Present at 38th Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
Dec-31-19 08:15PM The ups and downs for stocks of Triangle drugmakers in 2019American City Business Journals
Dec-12-19 07:34PM BioCryst Submits NDA for Hereditary Angioedema CandidateZacks
Dec-11-19 08:04PM BioCryst seeks federal approval for its lead drug candidateAmerican City Business Journals
05:16PM Here is What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX)Insider Monkey
Dec-11-19 12:00PM BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE AttacksGlobeNewswire
Dec-04-19 03:02PM Implied Volatility Surging for BioCryst (BCRX) Stock OptionsZacks
12:00PM BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
Nov-21-19 12:49PM Edited Transcript of BCRX earnings conference call or presentation 6-Nov-19 1:00pm GMTThomson Reuters StreetEvents
Nov-20-19 09:38PM Edited Transcript of BCRX earnings conference call or presentation 6-Nov-19 1:00pm GMTThomson Reuters StreetEvents
07:18PM BioCryst locks down another $20M on heels of public offeringAmerican City Business Journals
Nov-18-19 09:56PM Edited Transcript of BCRX earnings conference call or presentation 6-Nov-19 1:00pm GMTThomson Reuters StreetEvents
09:01PM BioCryst Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common StockGlobeNewswire
Nov-18-19 04:35PM Edited Transcript of BCRX earnings conference call or presentation 6-Nov-19 1:00pm GMTThomson Reuters StreetEvents
Nov-15-19 06:38PM Bank Of America Upgrades BioCryst As Financing Overhang Lifts PartiallyBenzinga
Nov-14-19 09:01PM BioCryst to Present at Upcoming Investor ConferencesGlobeNewswire
07:28PM Durham company sets stage for $55 million offeringAmerican City Business Journals
Nov-14-19 12:10AM BioCryst Prices Public Offering of Common StockGlobeNewswire
BioCryst Pharmaceuticals, Inc., a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan. It also develops BCX7353 and second generation kallikrein inhibitors, which are oral serine protease inhibitors targeting plasma kallikrein for hereditary angioedema; BCX9250 and BCX9499, which are activin receptor-like kinase-2 inhibitors for fibrodysplasia ossificans progressive; and Galidesivir, a RNA dependent-RNA polymerase inhibitor to treat RNA viruses. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Stocks in other countries: United Kingdom India Canada Australia
Market Cap
Volume (24h)